78725-46-9 Usage
Description
3-[3-(TRIFLUOROMETHYL)PHENOXY]BENZALDEHYDE is a clear yellow liquid that serves as an important intermediate in the synthesis of various organic compounds, particularly in the pharmaceutical and chemical industries.
Uses
Used in Pharmaceutical Industry:
3-[3-(TRIFLUOROMETHYL)PHENOXY]BENZALDEHYDE is used as a key intermediate in the synthesis of complex organic molecules for drug development. Its unique chemical structure allows for the creation of new pharmaceutical compounds with potential therapeutic applications.
Used in Chemical Industry:
3-[3-(TRIFLUOROMETHYL)PHENOXY]BENZALDEHYDE is used as a building block in the synthesis of various organic compounds, including dyes, pigments, and other specialty chemicals. Its versatility in chemical reactions makes it a valuable component in the development of new materials and products.
Specific Applications:
3-[3-(TRIFLUOROMETHYL)PHENOXY]BENZALDEHYDE is used in the synthesis of:
5,10,15,20-tetra[3-(3-trifluoromethyl)phenoxy]porphyrin: 3-[3-(TRIFLUOROMETHYL)PHENOXY]BENZALDEHYDE has potential applications in the development of new materials for solar energy conversion and photocatalysis.
4-4-naphthalen-2-yl-5-[3-(3-trifluoromethyl-phenoxy)-phenyl]-imidazol-1-yl-piperidine: This complex organic molecule may have potential applications in the pharmaceutical industry, particularly in the development of new drugs with unique therapeutic properties.
Check Digit Verification of cas no
The CAS Registry Mumber 78725-46-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,8,7,2 and 5 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 78725-46:
(7*7)+(6*8)+(5*7)+(4*2)+(3*5)+(2*4)+(1*6)=169
169 % 10 = 9
So 78725-46-9 is a valid CAS Registry Number.
InChI:InChI=1/C14H9F3O2/c15-14(16,17)11-4-2-6-13(8-11)19-12-5-1-3-10(7-12)9-18/h1-9H
78725-46-9Relevant articles and documents
Structure-aided optimization of non-nucleoside M. tuberculosis thymidylate kinase inhibitors
Song, Lijun,Merceron, Romain,Hulpia, Fabian,Lucía, Ainhoa,Gracia, Bego?a,Jian, Yanlin,Risseeuw, Martijn D.P.,Verstraelen, Toon,Cos, Paul,Aínsa, José A.,Boshoff, Helena I.,Munier-Lehmann, Hélène,Savvides, Savvas N.,Van Calenbergh, Serge
, (2021/08/27)
Mycobacterium tuberculosis thymidylate kinase (MtTMPK) has emerged as an attractive target for rational drug design. We recently investigated new families of non-nucleoside MtTMPK inhibitors in an effort to diversify MtTMPK inhibitor chemical space. We here report a new series of MtTMPK inhibitors by combining the Topliss scheme with rational drug design approaches, fueled by two co-crystal structures of MtTMPK in complex with developed inhibitors. These efforts furnished the most potent MtTMPK inhibitors in our assay, with two analogues displaying low micromolar MIC values against H37Rv Mtb. Prepared inhibitors address new sub-sites in the MtTMPK nucleotide binding pocket, thereby offering new insights into its druggability. We studied the role of efflux pumps as well as the impact of cell wall permeabilizers for selected compounds to potentially provide an explanation for the lack of correlation between potent enzyme inhibition and whole-cell activity.
